Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)

New York State Psychiatric Institute

Status and phase

Completed

Phase 2

Conditions

Obsessive-Compulsive Disorder

Treatments

Drug: Ketamine

Behavioral: Exposure and Response Prevention

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT02062658

#6811

K23MH092434 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study investigates if a single dose of IV Ketamine can rapidly improve Obsessive-Compulsive Disorder (OCD) symptoms and whether these effect can be maintained with a condensed course of a type of Cognitive Behavioral Therapy called Exposure and Response Prevention (EX/RP). You will be compensated for your time and travel. Participants must be between the ages of 18-55.

Enrollment

10 patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18-55
Physically healthy and not currently pregnant
Primary Diagnosis of OCD
Sufficient severity of symptoms
Currently off all psychotropic medication OR
Currently on adequate dose of medication for treatment of OCD, but have not achieved at least partial remission
Able to provide consent

Exclusion criteria

Psychiatric conditions that make participation unsafe (schizophrenia [either self or first degree relative e.g. siblings, parents], history of violence, severe depression, eating disorder, substance dependence [including nicotine])
Female patients who are either pregnant or nursing
Planning to commence EX/RP during the period of the study or those who have completed an adequate dose of EX/RP (defined as 8 or more sessions within 2 months) within 8 weeks prior to enrollment.

period of the study

Allergy to ketamine
Participants for whom being off of medication is not clinically recommended
Medical conditions that make participation unsafe (e.g. high blood pressure, head injury)
Currently on medications that make participation unsafe